Skip directly to content

Improving Patient Care in Chronic Obstructive Pulmonary Disease (COPD)

Pfizer is now inviting applications from Healthcare Organisations for support to improve patient care in COPD focusing on: 


The Review of Maintenance Treatment of Patients with COPD in line with GOLD1 recommendations.

The programmes currently available are:


Air Smart Spirometer

Air Smart is an app-linked portable spirometry device to aid healthcare professionals with the on-going monitoring of patients already diagnosed with Chronic Obstructive Pulmonary Disease (COPD), ensuring that their current management plan aligns with their severity of airflow obstruction and guideline recommendations.


The Pfizer-Novartis Alliance is making the Air Smart system available to healthcare organisations as a Medical and Educational Goods and Service (MEGS) with the aim of supporting improved care for patients with COPD. This MEGS will provide successful applicants with 8 devices and 160 turbines. Applications will be accepted from healthcare organisations such as CCGs, Health Boards, GP Federations or Hospital Trusts, but will NOT be accepted from individual GP practices. Awards will be made on a first come first served basis (limited to 1 grant per Healthcare Organisation) until the resource is full allocated.


Further turbines (beyond the 160 initially provided) are not included in the MEGS and will need to be purchased by the healthcare organisation directly from the manufacturer (NuvoAir AB). Air Smart comes with a user manual, including instructions for use and all that is needed to operate the spirometer and instructions to download the app. The app is free to download from the Apple App store as well as the Android Google Play store.


To apply please click the link below which will take you to the MEGS Enquiry form to fill out and submit.


Apply for Air Smart Spirometer


UK/LNG/17-0372(2) / August 2017


PP-PFE-GBR-0639 / Sept 2017